Statement: 1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 17/40 (42.50%)   Anaemia 2/40 (5.00%)   Febrile Neutropenia 3/40 (7.50%)   Neutropenia 2/40 (5.00%)   Thrombocytopenia 5/40 (12.50%)   Pericardial Effusion 1/40 (2.50%)   Abdominal Pain Lower 1/40 (2.50%)   Disease Progression 6/40 (15.00%)   Fatigue 1/40 (2.50%)   Pyrexia 3/40 (7.50%)   Septic Shock 1/40 (2.50%)   Streptococcal Infection 1/40 (2.50%)
Secondary_evidence: Adverse Events 1:   Total: 1/3 (33.33%)   Pain 0/3 (0.00%)   Cellulitis 0/3 (0.00%)   Influenza 0/3 (0.00%)   Osteomyelitis 0/3 (0.00%)   Pneumonia 0/3 (0.00%)   Humerus Fracture 0/3 (0.00%)   Brain Oedema 0/3 (0.00%)   Cerebral Haemorrhage 0/3 (0.00%)   Convulsion 0/3 (0.00%)   Dysarthria 0/3 (0.00%)   Hepatic Encephalopathy 0/3 (0.00%)   Confusional State 0/3 (0.00%)   Dyspnoea 1/3 (33.33%) Adverse Events 2:   Total: 1/1 (100.00%)   Pain 0/1 (0.00%)   Cellulitis 0/1 (0.00%)   Influenza 0/1 (0.00%)   Osteomyelitis 0/1 (0.00%)   Pneumonia 0/1 (0.00%)   Humerus Fracture 0/1 (0.00%)   Brain Oedema 0/1 (0.00%)   Cerebral Haemorrhage 0/1 (0.00%)   Convulsion 0/1 (0.00%)   Dysarthria 0/1 (0.00%)   Hepatic Encephalopathy 0/1 (0.00%)   Confusional State 0/1 (0.00%)   Dyspnoea 0/1 (0.00%)